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ABSTRACT
Objective: The aim is to study electrophysiological (EPh) indicators of the heart in pregnant women in the first trimester with orthodrome paroxysms of 
reciprocal atrioventricular tachycardia during the Valsalva test, after a single dose of propafenone and a combination of Valsalva test with propafenone.
Methods: Clinical survey, assessment of medical history, physical examination, electrocardiogram (ECG) in 12 leads, Holter ECG monitoring, 
echocardiography, expert ultrasound examination of the fetus, transesophageal EPh study of the heart, the blood test for electrolytes (potassium, 
sodium), thyroid hormones (T3, T4, thyroid-stimulating hormone) were included in this study. We examined 28 women during an early gestation.
Results: We found that the Valsalva manoeuver, Propanorm, and the combination of the Valsalva manoeuver and Propanorm produced an 
antiarrhythmic effect through the anterograde and retrograde conduction in reentry.
Discussion: The study is the first to reveal that the Valsalva manoeuver influences retrograde conduction in reentry in pregnant patients.
Conclusion: We proved that it is necessary to use the Valsalva manoeuver to stop paroxysms of orthodromic atrioventricular tachycardia (POAVRT)  in 
the first trimester of pregnancy. If the manoeuver is ineffective, it is advisable to use Propanorm or combination of Propanorm with Valsalva manoeuver.
Keywords: Orthodromic atrioventricular reentrant tachycardia paroxysms, Pregnancy, Valsalva manoeuver, Propanorm.
INTRODUCTION
During the paroxysms of reciprocal atrioventricular (AV) orthodrome 
tachycardia, the circulation of impulse occurs for the first in the 
anterograde direction — from the atria to the ventricles through the 
normal conduction system of the heart and then it goes retrogrades, 
from ventricles to the atria, in an abnormal way [1-5].
In previous studies [6-9], we have found that in women with POAVRT 
in the early stages of a gestation, there is the shortening of the effective 
refractory period (ERP) of the AV node, the upper window and the 
lower window of tachycardia, expanding the zone of tachycardia, the 
dispersion of refractory period of AV connection, and a retrograde 
pathway. These electrophysiological (EPh) changes indicate a high 
arrhythmogenic readiness of the heart.
The purpose was to study EPh indicators of the heart in pregnant women 
in the first trimester with orthodrome paroxysms of reciprocal AV 
tachycardia during the Valsalva test, after a single dose of propafenone 
and a combination of Valsalva test with propafenone.
METHODS
A clinical study was conducted in the period from 2013 to 2015 at the 
SBMH “Clinical Hospital No. 6 named after G. A. Zakharyin” in Penza.
There were examined 28 pregnant women with paroxysms of POAVRT, 
age from 19 to 32 years (26.5±2.5).
Studies included Clinical survey, assessment of medical history, 
physical examination, electrocardiogram (ECG) in 12 leads, Holter 
ECG monitoring, echocardiography, expert ultrasound examination 
of the fetus, transesophageal EPh study of the heart, the blood test 
for electrolytes (potassium, sodium), and thyroid hormones (T3, T4, 
thyroid-stimulating hormone). Variation statistics and correlation 
analysis were performed using the software package Microsoft Excel 
7.0 and Statistica 6.0. For a dynamic control, the results of the studies 
were used Holter monitoring of ECG and transesophageal electrical 
stimulation.
All patients included in the study who signed written consent.
RESULTS AND DISCUSSION
Table 1 shows ECG and EPh indicators of the heart during the first 
Valsalva test, after a single dose of propafenone and a combination of 
Valsalva test with propafenone in pregnant women in the first trimester 
with POAVRT.
Data obtained from the study (Table 1) show that during the Valsalva 
test in patients with POAVRT in the first trimester of pregnancy, there is 
a decrease in a heart rate by 18.1% (p<0.05), points of Wenckebach – by 
16.5% (p<0.05) and time of a discrete conduction by 24.3% (p<0.01). 
There is also a reduction in a ratio of St2-R2 max/St1-R1 min – by 
16.9% (p<0.05) and St2-R2/ERP of AV node by 29.4% (p<0.001). The 
increase in the ERP of AV node was by 20.1% (p<0.05), ERP of left 
atrium (LA) was by 20.3% (p<0.05). The increase in the upper window 
of tachycardia by 19.3% (p<0.05) and the lower windows of the 
tachycardia by 31.1% (p<0.01) has led to the reduction of tachycardia 
zone by 22.1% (p<0.01).
Patients with POAVRT in the first trimester of pregnancy during the 
Valsalva test 10 indicators from the main 16 EPh indicators (which 
were involved in relieving of POAVRT and maintaining sinus rhythm) 
have statistically significantly changed (62.5%).
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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EPh indicators of POAVRT Before 
pregnancy
The first trimester of pregnancy (n=28)
Outcome Valsalva test Propafenone Valsalva 
test+propafenone
1 2 3 4 5



































































































































































































Table 1: EPh parameters of the heart during the Valsalva test, after a single dose of propafenone and a combination of Valsalva test with 
propafenone in pregnant women in the first trimester with POAVRT (M±m)
(Contd...)
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Among the 28 patients with POAVRT in the first trimester during a 
Valsalva test was achieved a relief of the arrhythmia by blocking in the 
anterograde direction through the AV node in 11 women (39.3%), in 
3 (10.7%) – in retrograde, in 1 (3.6%) – in anterograde and retrograde, 
in 13 (46.4%) a relief failed.
In a numerous EPh studies [1,3,10,11] of antiarrhythmic drugs action 
at the cellular level, it is proved that there is no single antiarrhythmic 
drug, which has only one single point of application at the level of the 
cell membrane. Antiarrhythmic drugs which mainly affect Na channels 
(propafenone) simultaneously can modify K- and Ca-channels [2]. 
Amiodarone, in addition to the predominant influence on K-channels, 
also simultaneously modifies Na - and Ca-channels and meanwhile 
has α - and β-blocking action [2]. At the same time, these studies have 
not concerned the EPh assessment of vagal tests. As can be seen from 
the obtained data, vagal tests and antiarrhythmic drugs have multiple 
points of application [6,7,9]. A relief of the paroxysm through the 
blockade of anterograde and retrograde pathways proves this.
Side effects of Valsalva test were observed in 1 (3.6%) patient.
The conducted correlation analysis in the first trimester showed (Fig. 1) 
that between the dynamics of EPh indicators during the Valsalva test 
and the frequency of spontaneous seizures in a year, there is a strong 
inverse relationship (r=−0.9303, n=28, p<0.01).
After a single dose of propafenone in patients in the first trimester 
of pregnancy with POAVRT, it was revealed a decrease in the discrete 
holding time – by 39.6% (p<0.001), ratio St2-R2 max/St1-R1 min – by 
22.5% (p<0.05), and St2-R2/ERP of AV node by 46.9% (p<0.001) and 
was established the increase in the ERP of AV node by 18.1% (p<0.05), 
ERP of LA – by 17.0% (p<0.05). The increase in the upper window of 
tachycardia by 16.7% (p<0.05) and the lower window of tachycardia 
by 23.1% (p<0.01) has led to the narrowing of tachycardia by 29.5% 
(p<0.01).
After a single dose of propafenone in patients in the first trimester of 
pregnancy with POAVRT, among 16 ECG and EPh indicators, 8 of them 
were statistically significantly changed (50.0%). These 8 indicators were 
involved in relieving of POAVRT and in maintaining of a sinus rhythm.
Among the 28 patients in the first trimester with POAVRT, a relief of 
arrhythmia with a singular propafenone use has been achieved by 
the blockade of conduction in 18 women (64.8%) in the anterograde 
direction through the AV node, in 5 women (17.9%) in the retrograde 
direction, in 2 (7.1%) – in the anterograde and retrograde, in 3 – (10.7%) 
the blockade failed. Side effects from a single dose of propafenone were 
in 2 (7.1%) patients.
EPh indicators of POAVRT Before 
pregnancy
The first trimester of pregnancy (n=28)
Outcome Valsalva test Propafenone Valsalva 
test+propafenone
1 2 3 4 5
















































































*Statistically significant indicators. ERP: Effective refractory period, AV: Atrioventricular, LA: Left atrium, VA: Ventriculoatrial, HR: Heart rate, EPh: Electrophysiological, 
POVART: Paroxysms of orthodromic atrioventricular tachycardia 
Table 1: (Continued)
Fig. 1: The effect of Valsalva test on a correlation between 
electrophysiological - indicators of POAVRT and a frequency of 
paroxysms per year in the first trimester
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The conducted correlation analysis showed (Fig. 2) that in women, in the 
first trimester, who were taking propafenone had inverse relationships 
between the EPh indicators responsible for the maintenance of sinus 
rhythm and the frequency of spontaneous seizures in a year (r=−0.8530, 
n=28, p<0.01).
In our opinion, the evaluation of influencing the EPh indicators of 
POAVRT in combination of Valsalva test with propafenone is of a 
particular interest.
A combined use of propafenone during conduction of Valsalva test was 
revealed a reduction of the discrete time by 71.3% (p<0.001), ratio 
St2-R2 max/St1-R1 min – by 48.5% (p<0.001), and St2-R2/ERP of AV 
node – by 92.0% (p<0.001). The increase in the ERP of AV node was by 
17.3% (p<0.05), ERP of LA – by 24.9% (p<0.01). A slight increase in the 
upper window of tachycardia by 17.6% (p<0.05) and a marked increase 
in the bottom window of tachycardia by 25.6% (p<0.01) have led to the 
reduction of tachycardia zone by 50.6% (p<0.001).
In contrast to the Valsalva test alone and propafenone alone the 
combined use of Valsalva test with propafenone caused an increase in 
St1-R1 min by 18.8% (p<0.01), a reduction of the St2-R2 max by 20.6% 
(p<0.05) and St2-R2 increase by 195.% (p<0.05). As can be seen from 
the obtained data, compare a single use of propafenone with a combined 
use of Valsalva test with propafenone, we can see the additional time 
reduction of the discrete holding – by 18.5% (p<0.05), the ratio St2-R2 
max/St1-R1 min – by 17.5% (p<0.05) and St2-R2/ERP of AV node by 
23.5% (p<0.05).
Among the 16 EPh indicators statistically significantly have changed 
11 (68.8%). Among the 28 patients in the first trimester with POAVRT 
as the result of the combined use of Valsalva test with propafenone, a 
relief of the arrhythmia by blocking of a conduction in the anterograde 
direction through the AV node was achieved in 16 patients (57.1%), in 
7 (25.0%) – by the retrograde, in 4 (14.3%) – by the anterograde and 
retrograde, in 1 (3.6%) – the blocking failed. The adverse events in a 
concomitant use of Valsalva test with propafenone were observed in 
3 patients (10.7%).
The conducted correlation analysis showed (Fig. 3) that in the 
first trimester, the combined use of Valsalva test with propafenone 
demonstrates a strong inverse relationship between the EPh indicators 
responsible for the maintenance of a sinus rhythm and the frequency of 
spontaneous seizures in a year (r=−0.8901, n=28, p<0.01).
It is known that the dynamics of above-mentioned EPh indicators of 
POAVRT evidence of the relief efficacy and prophylactic efficacy of 
Valsalva test and propafenone [4]. Based on the obtained data, it is 
evident that in patients in the first trimester of pregnancy with POAVRT, 
the arrhythmia relief should begin with the Valsalva test; however, in 
the absence of an effect, we can go to the combined use of Valsalva test 
with propafenone. It should also be noted that the combined application 
of Valsalva test with propafenone is not only increasing the number of 
analyzed parameters but also potentiating the EPh effect.
CONCLUSION
In patients with paroxysms of reciprocal AV orthodrome tachycardia 
in early stages of a gestation as a result of the analysis of 16 EPh 
indicators, it was established that 10 of them (62.5%) have changed 
significantly during carrying out of a Valsalva test, after a single 
dose of propafenone – 8 (50.0%), in a combined use of Valsalva test 
with propafenone – 11 (68.8%). It is revealed that the Valsalva test, 
propafenone, and the combination of Valsalva test with propafenone 
implement antiarrhythmic effect through anterograde and retrograde 
link of circulation of excitation. For the first time, it was established that 
in pregnant patients, the Valsalva test has an impact on the retrograde 
part of circulation of excitation. It is established that between the 
number of EPh indicators involved in the circulation of excitation and 
the frequency of spontaneous seizures in a year, there is an inverse 
relationship. It is proved that in the first trimester of pregnancy, it 
is necessary to achieve a relief of POAVRT by Valsalva test and in the 
absence of the effect – by propafenone alone or by a combination of 
Valsalva test with propafenone.
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